This PD-L1-mediated adaptive immune resistance has been evident in multiple tumor types, including non-small cell lung carcinoma, Merkel cell carcinoma, anal squamous cell carcinoma, breast carcinoma, hepatocellular carcinoma, and melanoma [39,40]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.